AstraZeneca, Anheuser-Busch, Nissan: Intellectual Property

(Bloomberg) -- AstraZeneca Plc, the London-based drugmaker, has filed a notice with federal court in New Jersey that it will appeal a Feb. 13 ruling invalidating a patent covering its Pulmicort Respules, used to prevent asthma attacks. The appeal is to be made to the U.S. Court of Appeals for the Federal Circuit.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.